Primary De novo ductal adenocarcinoma of the lacrimal gland

Tripathy, Devjyoti; Agarwal, Sarla; Biala, Abhinav; Rath, Suryasnata; Mittal, Ruchi

doi:10.1016/j.anndiagpath.2020.151651

Cited by 5 publications

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Primary lacrimal adenocarcinoma accounts for 2%–14% of lacrimal epithelial tumors, and the incidence of local recurrence, lymph node metastasis, distant metastasis, and bone destruction is 3%, 24%, 50%–58%, and 26%, respectively. 9-11 Currently, the treatment for LGACC involves eye-sparing, surgical resection combined with radiotherapy and/or chemotherapy, while the main treatment for adenocarcinoma is surgical resection combined with radiotherapy. 12-14 The purpose of this study was to summarize the clinical features and prognosis of ocular adenoid cystic carcinoma and adenocarcinoma, and to analyze the differences in clinic features, treatment methods, prognosis, and influencing factors between the two using data from the Surveillance, Epidemiology, and End Results (SEER) database.…”

Section: Introductionmentioning

confidence: 99%

Differences in clinical features and prognosis between orbit adenoid cystic carcinoma and adenocarcinoma: a study from the SEER 18 database

Liu

Zhang

et al. 2022

Tumori

View full text Add to dashboard Cite

Purpose: To analyze the differences in clinical features, treatment methods, prognosis, and etiological factors between lacrimal gland, adenoid cystic carcinoma (LGACC), and orbit adenocarcinoma. Material and Methods: All cases of LGACC and orbit adenocarcinoma between 1975 and 2016 were obtained from the US National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) database. Results: The 3-, 5-, and 10-year overall survival (OS) rates for 118 LGACC cases were 82.2%, 70.2%, and 51.7%, respectively. The 3-, 5-, and 10-year OS rates for 29 orbit adenocarcinoma cases were 76.3%, 51.2%, and 51.2%, respectively. There was no statistically significant difference in the overall survival rate between LGACC and adenocarcinoma (P=0.566). Univariate analysis showed that the proportion of deaths was higher with increased age and year of diagnosis in LGACC (P=0.010 and P=0.000), while the death rate was higher for poorly differentiated adenocarcinoma (P=0.020). The survival rate for LGACC was lower in patients ⩾60 years of age than in those <60 years of age (P=0.035). There was no significant difference in survival rate between adenocarcinoma patients ⩾60 years and <60 years old (P=0.102). There was no significant correlation between the degree of tumor differentiation and the survival rate for LGACC or adenocarcinoma (P=0.401 or P=0.098, respectively). Conclusion: There is no significant difference in prognosis between LGACC and adenocarcinoma. The degree of tumor differentiation is not associated with prognosis for either LGACC or adenocarcinoma.

show abstract

Section: Introductionmentioning

confidence: 99%

Differences in clinical features and prognosis between orbit adenoid cystic carcinoma and adenocarcinoma: a study from the SEER 18 database

Liu

Zhang

et al. 2022

Tumori

View full text Add to dashboard Cite

show abstract

Primary ductal adenocarcinoma of the lacrimal gland with sarcomatoid differentiation: case report and genomic analysis

Aucoin,

Chawla,

Holleman

et al. 2023

Orbit

View full text Add to dashboard Cite

Primary Ductal Her‐2 Positive Adenocarcinoma of Salivary Gland: A Long Follow‐Up Case Report and Review of the Literature

Deantoni,

Midulla,

Mirabile

et al. 2024

Case Reports in Ophthalmological Medicine

View full text Add to dashboard Cite

Background: Epithelial tumors of lacrimal glands are rare and primary ductal adenocarcinoma of the lacrimal gland accounts for only 2% of all epithelial lacrimal gland tumors. Considering its rarity and lack of uniform diagnostic criteria, treatment protocols are not well defined.In this study, we describe a Her‐2 positive case and review previously reported cases.Methods: In 2012, a 42‐year‐old woman affected by primary ductal adenocarcinoma of the lacrimal gland was treated with transpalpebral anterior orbitotomy and adjuvant radiotherapy. In July 2013, she presented local relapse and she underwent orbital exenteration. In November 2013, for neck nodal progression, seven cycles of chemotherapy (cisplatin and epirubicin) associated with a humanized monoclonal antibody–targeting HER 2 therapy (trastuzumab and pertuzumab) were performed, with a marked response rate. Then, she underwent total parotidectomy with right neck lymphadenectomy and adjuvant hadrontherapy.Results: Nine years later (113 months) after treatment completion, the patient was alive without disease and with acceptable toxicity.Conclusions: In primary ductal adenocarcinoma of the lacrimal gland, early diagnosis and multimodal treatments could be crucial, considering its often aggressive tendency. Considering the lack of treatment guidelines, case report recording can be useful in patient management.

show abstract

Primary De novo ductal adenocarcinoma of the lacrimal gland

Cited by 5 publications

References 14 publications

Differences in clinical features and prognosis between orbit adenoid cystic carcinoma and adenocarcinoma: a study from the SEER 18 database

Differences in clinical features and prognosis between orbit adenoid cystic carcinoma and adenocarcinoma: a study from the SEER 18 database

Primary ductal adenocarcinoma of the lacrimal gland with sarcomatoid differentiation: case report and genomic analysis

Primary Ductal Her‐2 Positive Adenocarcinoma of Salivary Gland: A Long Follow‐Up Case Report and Review of the Literature

Contact Info

Product

Resources

About